vadadustat + furosemide

**Vadadustat + furosemide** is an unapproved, non-branded experimental combination of two small molecule drugs: vadadustat, an oral hypoxia-inducible factor prolyl-hydroxylase (HIF-PH) inhibitor that stimulates endogenous erythropoietin for anemia of chronic kidney disease, and furosemide, a loop diuretic inhibiting sodium and chloride reabsorption in the kidney to promote diuresis. The combination has been studied to assess drug-drug interactions, particularly because vadadustat inhibits organic anion transporter 3 (OAT3), which may affect the renal elimination and activity of furosemide when co-administered. There is no unique fixed-dose pharmaceutical product; its clinical investigation centers on interaction potential in healthy subjects and patients with chronic kidney disease[1][2][3][4][6].